https://www.thecatalystbrief.com/ Independent editorial intelligence platform serving biotech CEOs, investors, and strategic operators with signal, not noise. en-us Sun, 11 Oct 2026 01:02:13 GMT https://www.thecatalystbrief.com/article/americans-report-52-high-trust-in-science-while-u-s-divides-outrun-peer-nations https://www.thecatalystbrief.com/article/americans-report-52-high-trust-in-science-while-u-s-divides-outrun-peer-nations Regulatory & Policy Sun, 11 Oct 2026 01:00:50 GMT https://www.thecatalystbrief.com/article/aspen-and-bambusa-file-for-ipos-extending-2026-biotech-listing-push https://www.thecatalystbrief.com/article/aspen-and-bambusa-file-for-ipos-extending-2026-biotech-listing-push Healthcare Investment Sat, 10 Oct 2026 19:01:41 GMT https://www.thecatalystbrief.com/article/eli-lillys-expansion-strategy-mirrors-its-revenue-lead-as-glp-1-cash-funds-broader-r-and-d https://www.thecatalystbrief.com/article/eli-lillys-expansion-strategy-mirrors-its-revenue-lead-as-glp-1-cash-funds-broader-r-and-d Biopharmaceutical Industry Sat, 10 Oct 2026 19:01:41 GMT https://www.thecatalystbrief.com/article/bd-names-ferass-abuzaina-to-lead-surgery-business-signaling-an-internal-operator-bet https://www.thecatalystbrief.com/article/bd-names-ferass-abuzaina-to-lead-surgery-business-signaling-an-internal-operator-bet Medical Technology Sat, 10 Oct 2026 13:01:16 GMT https://www.thecatalystbrief.com/article/nancy-krieger-warns-census-changes-could-weaken-public-health-data-and-federal-resource-targeting https://www.thecatalystbrief.com/article/nancy-krieger-warns-census-changes-could-weaken-public-health-data-and-federal-resource-targeting Regulatory & Policy Sat, 10 Oct 2026 07:02:22 GMT https://www.thecatalystbrief.com/article/arm-outlines-data-reuse-playbook-for-gene-editing-aiming-to-cut-rare-disease-development-work https://www.thecatalystbrief.com/article/arm-outlines-data-reuse-playbook-for-gene-editing-aiming-to-cut-rare-disease-development-work Regulatory & Policy Sat, 10 Oct 2026 07:02:22 GMT https://www.thecatalystbrief.com/article/betsy-pleasants-reddit-nlp-abortion-access-barriers-public-health-surveillance https://www.thecatalystbrief.com/article/betsy-pleasants-reddit-nlp-abortion-access-barriers-public-health-surveillance Regulatory & Policy Sat, 10 Oct 2026 01:01:19 GMT https://www.thecatalystbrief.com/article/gsk-signs-chai-discovery-after-wet-lab-binders-across-tested-targets https://www.thecatalystbrief.com/article/gsk-signs-chai-discovery-after-wet-lab-binders-across-tested-targets AI in Drug Discovery Fri, 09 Oct 2026 19:01:34 GMT https://www.thecatalystbrief.com/article/trexbio-raises-116-7-million-in-ipo-funding-treg-programs-into-2029 https://www.thecatalystbrief.com/article/trexbio-raises-116-7-million-in-ipo-funding-treg-programs-into-2029 Healthcare Investment Fri, 09 Oct 2026 19:01:34 GMT https://www.thecatalystbrief.com/article/viatris-buys-pacira-for-1-65-billion-adding-exparel-and-zilretta-ahead-of-fam-decision https://www.thecatalystbrief.com/article/viatris-buys-pacira-for-1-65-billion-adding-exparel-and-zilretta-ahead-of-fam-decision Biopharmaceutical Industry Fri, 09 Oct 2026 13:02:17 GMT https://www.thecatalystbrief.com/article/trump-administration-investigates-9-universities-for-alleged-j-1-visa-fraud-pressuring-biomedical-research-staffing https://www.thecatalystbrief.com/article/trump-administration-investigates-9-universities-for-alleged-j-1-visa-fraud-pressuring-biomedical-research-staffing Regulatory & Policy Fri, 09 Oct 2026 13:02:17 GMT https://www.thecatalystbrief.com/article/newron-details-4-evenamide-deaths-across-trials-as-fda-hold-stays-on-enigma-trs-2 https://www.thecatalystbrief.com/article/newron-details-4-evenamide-deaths-across-trials-as-fda-hold-stays-on-enigma-trs-2 Biopharmaceutical Industry Fri, 09 Oct 2026 07:01:24 GMT https://www.thecatalystbrief.com/article/argenx-stops-phase-3-unity-in-sjogrens-cutting-off-a-1-4-billion-vyvgart-expansion-estimate https://www.thecatalystbrief.com/article/argenx-stops-phase-3-unity-in-sjogrens-cutting-off-a-1-4-billion-vyvgart-expansion-estimate Biopharmaceutical Industry Fri, 09 Oct 2026 07:01:24 GMT https://www.thecatalystbrief.com/article/endeavor-posts-phase-2b-taladegib-win-in-213-ipf-patients-setting-up-fda-phase-3-talks https://www.thecatalystbrief.com/article/endeavor-posts-phase-2b-taladegib-win-in-213-ipf-patients-setting-up-fda-phase-3-talks Biotech Innovation Fri, 09 Oct 2026 01:01:17 GMT https://www.thecatalystbrief.com/article/merck-is-barred-from-keytruda-sc-sales-in-8-european-countries-delaying-its-patent-extension-strategy https://www.thecatalystbrief.com/article/merck-is-barred-from-keytruda-sc-sales-in-8-european-countries-delaying-its-patent-extension-strategy Biopharmaceutical Industry Fri, 09 Oct 2026 01:01:17 GMT https://www.thecatalystbrief.com/article/iambic-targets-135-million-ipo-extending-2026-biotech-listing-momentum https://www.thecatalystbrief.com/article/iambic-targets-135-million-ipo-extending-2026-biotech-listing-momentum AI in Drug Discovery Thu, 08 Oct 2026 19:01:28 GMT https://www.thecatalystbrief.com/article/fda-extends-mifepristone-safety-review-into-2027-leaving-us-access-fight-unresolved https://www.thecatalystbrief.com/article/fda-extends-mifepristone-safety-review-into-2027-leaving-us-access-fight-unresolved Regulatory & Policy Thu, 08 Oct 2026 19:01:28 GMT https://www.thecatalystbrief.com/article/ono-pays-80-million-upfront-for-biohaven-igg-degraders-adding-a-phase-3-graves-asset-in-asia https://www.thecatalystbrief.com/article/ono-pays-80-million-upfront-for-biohaven-igg-degraders-adding-a-phase-3-graves-asset-in-asia Healthcare Investment Thu, 08 Oct 2026 13:01:31 GMT https://www.thecatalystbrief.com/article/argenx-advances-fb102-after-phase-2-celiac-endpoint-hit-setting-up-a-faster-run-at-il-15-pathway-competition https://www.thecatalystbrief.com/article/argenx-advances-fb102-after-phase-2-celiac-endpoint-hit-setting-up-a-faster-run-at-il-15-pathway-competition Biopharmaceutical Industry Thu, 08 Oct 2026 13:01:31 GMT https://www.thecatalystbrief.com/article/atsena-reports-lighthouse-responses-for-atsn-201-setting-up-a-2028-xlrs-filing-plan https://www.thecatalystbrief.com/article/atsena-reports-lighthouse-responses-for-atsn-201-setting-up-a-2028-xlrs-filing-plan Biotech Innovation Thu, 08 Oct 2026 07:01:35 GMT https://www.thecatalystbrief.com/article/tcgx-launches-600-million-asia-fund-extending-its-biotech-investing-model-into-china-and-beyond https://www.thecatalystbrief.com/article/tcgx-launches-600-million-asia-fund-extending-its-biotech-investing-model-into-china-and-beyond Healthcare Investment Thu, 08 Oct 2026 07:01:35 GMT https://www.thecatalystbrief.com/article/trump-administration-proposes-70000-opt-fee-raising-pressure-on-international-stem-training https://www.thecatalystbrief.com/article/trump-administration-proposes-70000-opt-fee-raising-pressure-on-international-stem-training Regulatory & Policy Thu, 08 Oct 2026 01:01:24 GMT https://www.thecatalystbrief.com/article/bayer-commits-2-2-billion-to-ohio-pharma-plant-adding-u-s-capacity-by-2031 https://www.thecatalystbrief.com/article/bayer-commits-2-2-billion-to-ohio-pharma-plant-adding-u-s-capacity-by-2031 Biopharmaceutical Industry Thu, 08 Oct 2026 01:01:24 GMT https://www.thecatalystbrief.com/article/matchpoint-nets-150m-series-b-to-advance-mpt-062-as-covalent-drug-investors-back-autoimmune-focus https://www.thecatalystbrief.com/article/matchpoint-nets-150m-series-b-to-advance-mpt-062-as-covalent-drug-investors-back-autoimmune-focus Healthcare Investment Wed, 07 Oct 2026 19:01:39 GMT https://www.thecatalystbrief.com/article/cerevance-revives-solengepras-with-phase-3-parkinsons-win-after-last-years-midstage-miss https://www.thecatalystbrief.com/article/cerevance-revives-solengepras-with-phase-3-parkinsons-win-after-last-years-midstage-miss Biotech Innovation Wed, 07 Oct 2026 19:01:39 GMT https://www.thecatalystbrief.com/article/caribou-ends-clinical-pipeline-after-financing-freeze-as-board-explores-strategic-alternatives https://www.thecatalystbrief.com/article/caribou-ends-clinical-pipeline-after-financing-freeze-as-board-explores-strategic-alternatives Healthcare Investment Wed, 07 Oct 2026 13:01:47 GMT https://www.thecatalystbrief.com/article/mimivax-misses-phase-2-glioblastoma-goal-with-survaxm-but-points-to-benefit-in-younger-subset https://www.thecatalystbrief.com/article/mimivax-misses-phase-2-glioblastoma-goal-with-survaxm-but-points-to-benefit-in-younger-subset Biotech Innovation Wed, 07 Oct 2026 13:01:47 GMT https://www.thecatalystbrief.com/article/nuvig-halts-nvg-2089-cidp-trial-keeping-midstage-itp-study-running https://www.thecatalystbrief.com/article/nuvig-halts-nvg-2089-cidp-trial-keeping-midstage-itp-study-running Biotech Innovation Wed, 07 Oct 2026 07:01:24 GMT https://www.thecatalystbrief.com/article/astrazeneca-opens-570000-square-foot-kendall-square-r-and-d-center-expanding-massachusetts-bet https://www.thecatalystbrief.com/article/astrazeneca-opens-570000-square-foot-kendall-square-r-and-d-center-expanding-massachusetts-bet Biopharmaceutical Industry Wed, 07 Oct 2026 07:01:24 GMT https://www.thecatalystbrief.com/article/arrivent-misses-phase-3-pfs-goal-for-firmonertinib-in-398-patient-nsclc-trial-sending-shares-down-57 https://www.thecatalystbrief.com/article/arrivent-misses-phase-3-pfs-goal-for-firmonertinib-in-398-patient-nsclc-trial-sending-shares-down-57 Biotech Innovation Wed, 07 Oct 2026 01:01:23 GMT https://www.thecatalystbrief.com/article/ftc-sends-warning-letters-to-24-healthcare-organizations-over-price-transparency-expanding-pressure-beyond-cms-rules https://www.thecatalystbrief.com/article/ftc-sends-warning-letters-to-24-healthcare-organizations-over-price-transparency-expanding-pressure-beyond-cms-rules Regulatory & Policy Wed, 07 Oct 2026 01:01:23 GMT https://www.thecatalystbrief.com/article/abbott-wins-fda-clearance-for-cardiomems-app-upgrade-adding-at-home-pressure-visibility https://www.thecatalystbrief.com/article/abbott-wins-fda-clearance-for-cardiomems-app-upgrade-adding-at-home-pressure-visibility Medical Technology Tue, 06 Oct 2026 19:01:31 GMT https://www.thecatalystbrief.com/article/novos-denecimig-review-slips-after-fda-flags-manufacturing-remediation https://www.thecatalystbrief.com/article/novos-denecimig-review-slips-after-fda-flags-manufacturing-remediation Regulatory & Policy Tue, 06 Oct 2026 19:01:31 GMT https://www.thecatalystbrief.com/article/trex-bio-targets-111-3m-ipo-as-retension-and-lycia-join-a-busy-2026-listing-window https://www.thecatalystbrief.com/article/trex-bio-targets-111-3m-ipo-as-retension-and-lycia-join-a-busy-2026-listing-window Healthcare Investment Tue, 06 Oct 2026 13:01:32 GMT https://www.thecatalystbrief.com/article/uk-backs-continuous-monitoring-for-ai-medical-devices-replacing-a-one-time-review-model https://www.thecatalystbrief.com/article/uk-backs-continuous-monitoring-for-ai-medical-devices-replacing-a-one-time-review-model Regulatory & Policy Tue, 06 Oct 2026 13:01:32 GMT https://www.thecatalystbrief.com/article/viking-therapeutics-closed-about-575-million-after-vk2735-phase-1-data-but-ended-september-down-3-18 https://www.thecatalystbrief.com/article/viking-therapeutics-closed-about-575-million-after-vk2735-phase-1-data-but-ended-september-down-3-18 Healthcare Investment Tue, 06 Oct 2026 07:01:21 GMT https://www.thecatalystbrief.com/article/stem-cell-advocates-seek-fda-roundtables-as-peptide-policy-opens-a-new-regulatory-push https://www.thecatalystbrief.com/article/stem-cell-advocates-seek-fda-roundtables-as-peptide-policy-opens-a-new-regulatory-push Regulatory & Policy Tue, 06 Oct 2026 07:01:21 GMT https://www.thecatalystbrief.com/article/shionogi-buys-intrabio-for-2-billion-extending-its-overseas-rare-disease-buildout https://www.thecatalystbrief.com/article/shionogi-buys-intrabio-for-2-billion-extending-its-overseas-rare-disease-buildout Biopharmaceutical Industry Tue, 06 Oct 2026 01:01:24 GMT https://www.thecatalystbrief.com/article/lilly-expands-gate-alliance-past-870-million-adding-targets-for-extracellular-protein-degraders https://www.thecatalystbrief.com/article/lilly-expands-gate-alliance-past-870-million-adding-targets-for-extracellular-protein-degraders Healthcare Investment Tue, 06 Oct 2026 01:01:24 GMT https://www.thecatalystbrief.com/article/genentech-pays-100-million-upfront-for-alectors-al050-extending-a-blood-brain-barrier-bet https://www.thecatalystbrief.com/article/genentech-pays-100-million-upfront-for-alectors-al050-extending-a-blood-brain-barrier-bet Biopharmaceutical Industry Mon, 05 Oct 2026 19:02:35 GMT https://www.thecatalystbrief.com/article/deisseroth-hegemann-and-nagel-win-2026-nobel-prize-in-medicine-for-optogenetics https://www.thecatalystbrief.com/article/deisseroth-hegemann-and-nagel-win-2026-nobel-prize-in-medicine-for-optogenetics Biotech Innovation Mon, 05 Oct 2026 19:02:35 GMT https://www.thecatalystbrief.com/article/csl-pays-355-million-upfront-for-alentis-lixudebart-expanding-its-kidney-disease-push https://www.thecatalystbrief.com/article/csl-pays-355-million-upfront-for-alentis-lixudebart-expanding-its-kidney-disease-push Biopharmaceutical Industry Mon, 05 Oct 2026 13:01:46 GMT https://www.thecatalystbrief.com/article/vaxcyte-posts-phase-3-vax-31-win-against-prevnar-20-and-capvaxive-setting-up-a-2028-fda-filing https://www.thecatalystbrief.com/article/vaxcyte-posts-phase-3-vax-31-win-against-prevnar-20-and-capvaxive-setting-up-a-2028-fda-filing Biotech Innovation Mon, 05 Oct 2026 13:01:46 GMT https://www.thecatalystbrief.com/article/roivant-enters-commercial-era-with-lisraya-as-three-lead-assets-anchor-its-next-phase https://www.thecatalystbrief.com/article/roivant-enters-commercial-era-with-lisraya-as-three-lead-assets-anchor-its-next-phase Biopharmaceutical Industry Mon, 05 Oct 2026 07:01:41 GMT https://www.thecatalystbrief.com/article/ai3bio-unveils-48-million-financing-targets-th17-cells-with-cgas-sting-mrna-approach https://www.thecatalystbrief.com/article/ai3bio-unveils-48-million-financing-targets-th17-cells-with-cgas-sting-mrna-approach Biotech Innovation Mon, 05 Oct 2026 07:01:41 GMT https://www.thecatalystbrief.com/article/trump-announces-90-medicare-premium-payments-for-more-than-20-million-seniors-days-before-midterms https://www.thecatalystbrief.com/article/trump-announces-90-medicare-premium-payments-for-more-than-20-million-seniors-days-before-midterms Regulatory & Policy Sun, 04 Oct 2026 19:01:24 GMT https://www.thecatalystbrief.com/article/pennsylvania-reports-943-measles-cases-and-fifth-death-as-officials-face-an-unknowable-outbreak-size https://www.thecatalystbrief.com/article/pennsylvania-reports-943-measles-cases-and-fifth-death-as-officials-face-an-unknowable-outbreak-size Regulatory & Policy Sun, 04 Oct 2026 01:00:46 GMT https://www.thecatalystbrief.com/article/mary-claire-king-described-brca-works-reach-as-nobel-speculation-returns-ahead-of-this-years-prize https://www.thecatalystbrief.com/article/mary-claire-king-described-brca-works-reach-as-nobel-speculation-returns-ahead-of-this-years-prize Biotech Innovation Sat, 03 Oct 2026 19:02:02 GMT https://www.thecatalystbrief.com/article/nih-awarded-roughly-34-billion-in-fy2026-grants-but-funded-about-58000-projects-after-delays https://www.thecatalystbrief.com/article/nih-awarded-roughly-34-billion-in-fy2026-grants-but-funded-about-58000-projects-after-delays Regulatory & Policy Sat, 03 Oct 2026 19:02:02 GMT https://www.thecatalystbrief.com/article/bmo-backs-mercks-post-keytruda-setup-flags-bristol-myers-30-plus-billion-2028-exposure https://www.thecatalystbrief.com/article/bmo-backs-mercks-post-keytruda-setup-flags-bristol-myers-30-plus-billion-2028-exposure Healthcare Investment Sat, 03 Oct 2026 13:02:20 GMT